Compare Moderna, Inc. (MRNA) vs Seagate Technology Holdings PLC (STX) Price & Performance

Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.

The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.

Seagate Technology (STX) trades at $774.83, down 4.03% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $5.71 vs. $5.10 estimate, and robust profitability metrics including 26.11% net margin and 371.53% ROE. Technical indicators signal bearish momentum with the price below key resistance levels, while analyst consensus remains positive with 53.85% buy ratings and $1,130 price target.

Despite near-term competitive pressures, Seagate maintains strong positioning in AI storage markets with projected 2026 revenue growth to $12.2B. The primary risk involves Toshiba's capacity expansion potentially eroding pricing power. Current valuation multiples appear elevated (P/E 55.74, P/S 14.55) but are supported by exceptional profitability and AI-driven demand outlook.